Scholarlink

Introduction <p>Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B&#xa0;cell lymphomas; however, evidence on their comparative efficacy remains limited. This meta-analysis compared the efficacy of BTKi monotherapies across treatment naïve (TN) and/or relapsed and refractory (R/R) B&#xa0;cell lymphomas.</p> Methods <p>Clinical trials reporting complete response (CR) or overall response rate (ORR) for zanubrutinib, acalabrutinib, or ibrutinib monotherapy in chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Waldenström macroglobulinemia (WM) were included. Response rates from similar duration of follow-up were pooled across applicable studies. Naïve odds ratios (ORs) comparing CR and ORR of zanubrutinib with acalabrutinib or ibrutinib were calculated within each B&#xa0;cell lymphoma indication and then meta-analyzed across all indications using a random effects model.</p> Results <p>The meta-analysis found zanubrutinib to be associated with statistically significant improvements in investigator-assessed CR and ORR vs acalabrutinib and ibrutinib across B&#xa0;cell lymphomas, using data with similar duration of follow-up. The pooled OR estimates [95%&#xa0;CI] for CR were 1.80 [1.03, 3.13] for zanubrutinib vs acalabrutinib and 2.85 [1.16, 7.04] for zanubrutinib vs ibrutinib across all B&#xa0;cell indications. ORs significantly favored zanubrutinib over acalabrutinib and ibrutinib for R/R MCL, and over ibrutinib for R/R MZL. The pooled OR estimates for ORR were 1.59 [1.00, 2.53] for zanubrutinib vs acalabrutinib and 2.25 [1.40, 3.61] for zanubrutinib vs ibrutinib. ORs significantly favored zanubrutinib over acalabrutinib and ibrutinib for TN CLL, and over ibrutinib for R/R MCL and R/R MZL.</p> Conclusion <p>Consistent with the results of existing head-to-head trials, zanubrutinib demonstrated either numerically or statistically significant improved CR and ORR compared to acalabrutinib and ibrutinib across B&#xa0;cell lymphomas. Similar trends were observed within each indication. These findings suggest that zanubrutinib is the most effective BTKi treatment option for patients across B&#xa0;cell lymphomas.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月7日

查看全文
  • Pier Luigi Zinzani,
  • Rhys Williams,
  • Mei Xue,
  • Binod Neupane,
  • Priccila Zuchinali,
  • Kyle Fahrbach,
  • Heather Burnett,
  • Dennis Sadic,
  • Leyla Mohseninejad,
  • Keri Yang

摘要

Introduction

Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B cell lymphomas; however, evidence on their comparative efficacy remains limited. This meta-analysis compared the efficacy of BTKi monotherapies across treatment naïve (TN) and/or relapsed and refractory (R/R) B cell lymphomas.

Methods

Clinical trials reporting complete response (CR) or overall response rate (ORR) for zanubrutinib, acalabrutinib, or ibrutinib monotherapy in chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Waldenström macroglobulinemia (WM) were included. Response rates from similar duration of follow-up were pooled across applicable studies. Naïve odds ratios (ORs) comparing CR and ORR of zanubrutinib with acalabrutinib or ibrutinib were calculated within each B cell lymphoma indication and then meta-analyzed across all indications using a random effects model.

Results

The meta-analysis found zanubrutinib to be associated with statistically significant improvements in investigator-assessed CR and ORR vs acalabrutinib and ibrutinib across B cell lymphomas, using data with similar duration of follow-up. The pooled OR estimates [95% CI] for CR were 1.80 [1.03, 3.13] for zanubrutinib vs acalabrutinib and 2.85 [1.16, 7.04] for zanubrutinib vs ibrutinib across all B cell indications. ORs significantly favored zanubrutinib over acalabrutinib and ibrutinib for R/R MCL, and over ibrutinib for R/R MZL. The pooled OR estimates for ORR were 1.59 [1.00, 2.53] for zanubrutinib vs acalabrutinib and 2.25 [1.40, 3.61] for zanubrutinib vs ibrutinib. ORs significantly favored zanubrutinib over acalabrutinib and ibrutinib for TN CLL, and over ibrutinib for R/R MCL and R/R MZL.

Conclusion

Consistent with the results of existing head-to-head trials, zanubrutinib demonstrated either numerically or statistically significant improved CR and ORR compared to acalabrutinib and ibrutinib across B cell lymphomas. Similar trends were observed within each indication. These findings suggest that zanubrutinib is the most effective BTKi treatment option for patients across B cell lymphomas.